Actinic Keratosis Market Ready to Surpass US$ 11,628.0 Mn by 2030
Actinic Keratosis Market |
Actinic keratosis (AK) is a common skin condition that
is characterized by rough, scaly patches or lesions that develop on the skin
that is exposed to the sun. AK is considered a precancerous condition, as it
can progress to squamous cell carcinoma if left untreated. The actinic
keratosis market has been on the rise in recent years, and there are several
factors contributing to this growth.
Global Actinic Keratosis Market is estimated to be valued at US$
8,070.0 Mn in 2022 and expected to exhibit a CAGR of 4.7% over the forecast
period (2022-2030).
One of the primary drivers of the Actinic
Keratosis Market is the aging population. As people age, their skin
becomes thinner and less able to protect itself from the sun's damaging rays.
This makes older adults more susceptible to developing actinic keratoses.
According to the American Academy of Dermatology, approximately 40% of people
over the age of 40 will develop at least one actinic keratosis in their
lifetime.
Another factor contributing to the growth of the Actinic Keratosis Market is increased awareness and diagnosis. As more people
become aware of the condition and its potential to progress to skin cancer,
they are seeking medical attention and diagnosis. Dermatologists are also
becoming more skilled at identifying actinic keratoses, which has led to more
accurate diagnoses and treatment.
Skin cancer is one of the most common types of cancer in the
United States, and the incidence of skin cancer is on the rise. This has led to
increased awareness of the importance of protecting the skin from the sun's
damaging rays and seeking medical attention for suspicious skin lesions.
Actinic keratosis is considered a precursor to squamous cell carcinoma, one of
the most common types of skin cancer. As such, the rising incidence of skin
cancer has also led to increased diagnosis and treatment of actinic keratoses.
Bausch Health Companies Inc., Perrigo Company plc., Sun
Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Spear
Pharmaceuticals, Tolmar Pharmaceuticals, Inc., Bioforntera AG, Cypher
Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited
are among the companies involved.
Comments
Post a Comment